Sodium–glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin and dapagliflozin, not only improve glycemic control but are also guideline-recommended foundation therapy to slow CKD progression and reduce cardiovascular events, partly independent of their glucose-lowering effects [21,22]. Here, SLC5A2 is linked to chronic kidney disease.